Search peptides, terms, sources/
Metabolic and incretin

Cagrilintide

Also known as: AM833 · studied in fixed-dose combination with semaglutide under the name CagriSema · no standalone UK/US brand name

Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Moderate evidence (level 3 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Cagrilintide is recorded as not licensed in the UK (checked 14 August 2026).

Best study type
Human trials1 human trial of cagrilintide alone · 1 combination trial (with semaglutide) · 1 animal

What is Cagrilintide?

Cagrilintide is an investigational long-acting amylin analogue, studied for weight management alone and in combination with semaglutide. It is not licensed in the UK, and the evidence comes from sponsor-funded randomised trials, a Phase 2 trial of cagrilintide alone and a Phase 3 trial of the combination.

It belongs to the DACRA family (dual amylin and calcitonin receptor agonists). The Phase 3 trial tested a fixed-dose combination with semaglutide, under the study name CagriSema, against each component alone and against placebo.

Class
Amylin receptor agonist (DACRA)
Origin
Analogue / modified
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Cagrilintide work?

Cagrilintide copies amylin, a hormone released with insulin that helps people feel full. It activates amylin and calcitonin receptors, and animal work shows brain amylin receptors are needed for its weight effect. Its action is separate from GLP-1, which is why the two are studied together.

The mechanism in more detail

Cagrilintide activates both the amylin receptor (specifically the AMY1R and AMY3R subtypes) and the calcitonin receptor, with reported roughly equivalent potency across these targets in signalling assays, a non-selective binding pattern that distinguishes it from more receptor-selective amylin analogues in development. Mechanistic studies in preclinical models have shown that activation of brain amylin receptors 1 and 3 specifically is required for cagrilintide’s bodyweight-lowering effect. Downstream effects reported in the literature include improved satiety, delayed gastric emptying, and modulation of energy expenditure.

Because amylin-receptor and GLP-1-receptor mechanisms are separate and non-overlapping, they are reported in the literature as having an additive effect on appetite reduction when combined, which is the pharmacological rationale for studying cagrilintide together with semaglutide as CagriSema. This additive-mechanism claim describes the pharmacological rationale for that combination, not a demonstrated standalone-cagrilintide effect beyond what its own Phase 2 trial has shown.

Mechanisms and targets

Additive mechanism with GLP-1 receptor agonismAmylin receptor agonismAppetite/satiety regulationCalcitonin receptor agonismDACRA pharmacologyAmylin receptor 1 (AMY1R)Amylin receptor 3 (AMY3R)Calcitonin receptor (CTR)

Classification and structure

Names
Cagrilintide; AM833 (research/development code); studied in fixed-dose combination with semaglutide under the name CagriSema; no standalone UK/US brand name (unlicensed as a standalone product as of August 2026)
Class
Amylin receptor agonist (DACRA)
Origin
Analogue / modified
Structure
A stable, lipidated, long-acting amylin analogue (Kruse et al., J Med Chem 2021). Exact sequence and modification detail is not given here.
Routes used in the research
Subcutaneous injection in both the standalone Phase 2 trial and the REDEFINE 1 combination trial.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Cagrilintide has 3 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

3 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
10110

1 of the findings graded Strong tested a combination with another substance, not Cagrilintide alone, so it is not counted in the evidence grade at the top of the page.

Standalone Phase 2 weight trial Moderate

In a dose-finding Phase 2 trial, standalone cagrilintide, tested at several doses, produced significant reductions in body weight in adults with overweight/obesity versus placebo. Permanent treatment discontinuation occurred in 10% of participants overall, 4% due to adverse events.

Study type
Human trial
Population
Adults aged 18 or above without diabetes, BMI 30 or above (or 27 or above with hypertension or dyslipidaemia), randomised across multiple cagrilintide dose groups (approximately 100 to 102 per group), a liraglutide active comparator arm (n=99), and a placebo arm (n=101); 57 sites across ten countries including the UK.
Source
1 Lau et al., 2021

Limitation: Sponsor-funded (Novo Nordisk).

Limitations in full

Sponsor-funded (Novo Nordisk). Weight loss ranged from 6.0% to 10.8% across cagrilintide doses, against 3.0% on placebo.

Brain amylin receptor mechanism Preliminary

Cagrilintide's bodyweight-lowering effect depends on activation of brain amylin receptors 1 and 3 (AMY1R, AMY3R), based on receptor-binding and functional studies.

Study type
Animal
Population
Receptor-binding assays and preclinical (rodent) models.
Source
2 eBioMedicine, 2025

Limitation: Preclinical and in-vitro only; no human receptor-occupancy data are cited.

Limitations in full

Preclinical and in-vitro only; no human receptor-occupancy data are cited. This is mechanistic background, not a clinical efficacy or safety claim.

The REDEFINE 1 trial Strong Combination, not Cagrilintide alone

In a Phase 3 randomised, double-blind trial (REDEFINE 1), the fixed-dose combination of cagrilintide and semaglutide (CagriSema) produced a mean weight reduction of 22.7% at 68 weeks in adults with overweight or obesity and at least one weight-related comorbidity, without diabetes, compared with 11.8% for cagrilintide alone, 16.1% for semaglutide alone, and 2.3% for placebo. 60% of CagriSema-treated participants achieved at least 20% weight loss, and 23% achieved 30% or more; 88% of participants with prediabetes at baseline returned to normoglycaemia.

Study type
Human trial
Population
3,417 adults with obesity or overweight and 1 or more comorbidities, without type 2 diabetes; multicentre, double-blind, placebo- and active-controlled (four-arm design including a cagrilintide-alone arm), phase 3.
Source
3 Garvey et al., 2025

Limitation: Sponsor-funded (Novo Nordisk); studies the fixed combination, not cagrilintide as a standalone agent.

Limitations in full

Sponsor-funded (Novo Nordisk); studies the fixed combination, not cagrilintide as a standalone agent. CagriSema is not licensed anywhere as of August 2026. This grade applies to the combination product's effect, not to standalone cagrilintide; the trial's own cagrilintide-alone arm (11.8% weight loss) is a useful internal comparator but is a single arm within this one trial.

What safety findings have been reported?

2 safety findings are recorded for Cagrilintide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Phase 2 discontinuation rate

In the standalone Phase 2 dose-finding trial, permanent discontinuation occurred in 10% of participants overall (4% specifically due to adverse events).

Source
1 Lau et al., 2021

CagriSema gastrointestinal adverse events

In REDEFINE 1, adverse events were mainly gastrointestinal and occurred more frequently with CagriSema than placebo: nausea 55% vs 12.6%, constipation 30.7% vs 11.6%, vomiting 26.1% vs 4.1% (79.6% of the CagriSema group reported at least one gastrointestinal adverse event, versus 39.9% for placebo). Events were reported as mostly transient and mild-to-moderate. Discontinuation due to adverse events was 6% for CagriSema versus 3.7% for placebo.

Source
3 Garvey et al., 2025

What is Cagrilintide's UK regulatory status?

Marketing authorisation
Not licensed, as a standalone agent or as the CagriSema combination. No MHRA marketing authorisation exists for cagrilintide in any form as of August 2026.
Prescription status
Not applicable; no licensed UK product exists to classify.
Medicine class
Unlicensed/investigational medicinal product.
MHRA position
No MHRA-authorised product exists. Cagrilintide (standalone) remains in earlier-stage clinical development than CagriSema. CagriSema is in Phase 3 development. Novo Nordisk announced on 18 December 2025 that it had submitted a New Drug Application for CagriSema to the US FDA. No UK submission status has been confirmed.
Authorised use
None.
Research use
Studied under formal clinical-trial frameworks (Phase 2 standalone, Phase 3 in combination) by its developer, Novo Nordisk.
Other restrictions
As an unlicensed medicinal product, cagrilintide falls under the general UK framework for unlicensed medicines (Human Medicines Regulations 2012), a general statutory framework applied by inference to cagrilintide's category, not a cagrilintide-specific regulatory document naming the compound.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Cagrilintide is recorded as not licensed in the UK (checked 14 August 2026).

References

4 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 398(10317):2160-2172Human clinical trial, RCT · DOI 10.1016/S0140-6736(21)01751-7 · PMID 34798060 · Original ↗
  2. eBioMedicine (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine (The Lancet Discovery Science family)Animal-preclinical, In-vitro · Original ↗
  3. Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; REDEFINE 1 Study Group (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine, 393(7):635-647Human clinical trial, RCT · DOI 10.1056/NEJMoa2502081 · PMID 40544433 · Original ↗
  4. Novo Nordisk A/S A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function (ClinicalTrials.gov registry entry). ClinicalTrials.gov (U.S. National Library of Medicine) · Original ↗

Questions about Cagrilintide

What is Cagrilintide?

Cagrilintide is an investigational long-acting amylin analogue, studied for weight management alone and in combination with semaglutide. It is not licensed in the UK, and the evidence comes from sponsor-funded randomised trials, a Phase 2 trial of cagrilintide alone and a Phase 3 trial of the combination. Read what it is.

Is Cagrilintide licensed in the UK?

PeptGuru records Cagrilintide's UK status as: Not licensed in the UK. Not licensed, as a standalone agent or as the CagriSema combination. UK status checked 14 August 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Cagrilintide show?

PeptGuru records 3 research findings for Cagrilintide: 2 from human trials and 1 from an animal study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Cagrilintide?

2 safety findings are recorded, including: phase 2 discontinuation rate; CagriSema gastrointestinal adverse events. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Cagrilintide?

All 4 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · Phase 2 trial size corrected to 706 randomised participants.

How findings are graded: the grading method. All changes.

  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK

Compare Cagrilintide with Liraglutide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.